http://www.nibr.com/rss/NIBR-Stories-EN.xml Find the latest news about NIBR. http://www.nibr.com/images/_common/nibr-logo-new.gif http://www.nibr.com Feb-17-2012 en-us http://www.nibr.com/newsroom/stories/2012/2012Jan20_ChagasScience.shtml Feb-17-2012 Mammalian cells become increasingly filled with proliferating T cruzi parasites during cell culture. Image shown is after 8 days of infection. Parasites are visualized as smaller, yellow/ green dots surrounding the mammalian nuclei. http://www.nibr.com/newsroom/stories/2012/2012Jan20_ChagasPeople.shtml Feb-17-2012 Researchers working across NIBR are tackling this important disease. http://nibr.com/newsroom/stories/2012/2012Jan13_MFishman10Years.shtml Jan-13-2012 Mark Fishman started heading up research and development at Novartis, as President of the Novartis Institutes for BioMedical Research (NIBR), 10 years ago. http://nibr.com/newsroom/stories/2011/2011Dec15_EarlyCareerAward.shtml Dec-18-2011 Professor David Chen, Seoul National University and Professor David Spiegel, Yale University received the 2011 Novartis Early Career Award in Organic Chemistry. http://nibr.com/newsroom/stories/2011/2011Nov18_Malaria-Tools.shtml Nov-17-2011 NIBR, along with collaborators, discovered a new class of dual-acting antimalarial compounds that target both liver- and blood-infections - the imidazolopiperazines (IZPs). http://nibr.com/newsroom/stories/2011/2011Nov11_Innovative-Culture.shtml Nov-11-2011 If you ask associates at Novartis Institutes for BioMedical Research (NIBR) what energizes them about the organization, they are likely to describe our strategic approach to drug discovery - focus on unmet medical need of patients worldwide in areas where we understand the mechanism of disease. It has resulted in one of the leading pipelines in the pharmaceutical industry today, continually reinforced by a culture that demands innovation. http://nibr.com/newsroom/stories/2011/2011Oct21_Typhoid_Vaccine_ClinicalTrial.shtml Oct-24-2011 Pakistani health authorities and a NVGH Pakistani scientist collaborate to bring a typhoid-fever-vaccine clinical trial to the region. http://nibr.com/newsroom/stories/2011/2011Oct07_DonaldGanem.shtml Oct-07-2011 NIBR cements its position as a hub of innovative research in the Bay Area by establishing Infectious Disease (ID) Headquarters in Emeryville, led by Don Ganem. http://nibr.com/newsroom/stories/2011/2011Sept23_JobDiscovering.shtml Sept-23-2011 The NIBR Developing World Mini-Sabbatical Program combines a scientific sabbatical combined with social impact. Grazia Piizzi, a NIBR investigator in Global Discovery Chemistry- Oncology and Exploratory Chemistry, demonstrates the program's exponential value. http://www.nibr.com/newsroom/stories/2011/2011Sept02_Imaging.shtml Sept-03-2011 The NIBR Developing World Mini-Sabbatical Program combines a scientific sabbatical combined with social impact. Grazia Piizzi, a NIBR investigator in Global Discovery Chemistry- Oncology and Exploratory Chemistry, demonstrates the program's exponential value. http://nibr.com/newsroom/stories/2011/2011Aug04_GraziaPiizzi.shtml Aug-09-2011 The NIBR Developing World Mini-Sabbatical Program combines a scientific sabbatical combined with social impact. Grazia Piizzi, a NIBR investigator in Global Discovery Chemistry- Oncology and Exploratory Chemistry, demonstrates the program's exponential value. http://nibr.com/newsroom/stories/2011/2011Jun10_JobCandidatesViaTwitter.shtml Jun-06-2011 "A 2010 survey conducted by Jobvite, a social search platform for recruitment, showed that 83% of recruiting professional are now using or are planning to use social media for recruiting; social network recruiting is gaining momentum," said Harold Mellor, associate director of staffing and NIBR Jobs Tweeter. http://www.nibr.com/newsroom/stories/2011/2011May13_ScientistBestPlace.shtml May-06-2011 "By forging new relationships and finding novel uses for existing technologies, (Novartis) is among this year's top companies that are finding creative ways to advance science," according to The Scientist. http://nibr.com/newsroom/stories/index.shtml April-29-2011 Dramatic shifts in the size of global, ethnic and regional populations are expected during the next 50 years. The Novartis Institutes for BioMedical Research (NIBR) is holding its inaugural Health Equity Symposium May 3-4, which will gather scientists, clinicians and policymakers to discuss what industry, academia and government can do to help shape the way biomedical research is conducted. The goal is to better serve the unique needs of each group and ensure a more equitable delivery of health care. Leading researchers and policymakers, including Dr. Julio Frenk, Dean, Harvard School of Public Health and Mexico's former Minister of Health, are among the speakers. The symposium will be webcast live, then archived for later viewing. http://nibr.com/downloads/newsroom/resources/PoC2010_0405_e.pdf April-22-2011 At the Novartis Institutes for BioMedical Research (NIBR), the primary objective of a Proof of Concept (PoC) study is to test hypotheses of how a drug may work in the body and to expedite the generation of clinical evidence regarding patient benefit. NIBR had 12 PoCs in 2010. Several outlined here illustrate NIBR's pathways approach to drug discovery. http://nibr.com/newsroom/stories/2011/2011Mar11_PostDocstoScientist.shtml Mar-11-2011 Offering health, retirement, relocation and many other benefits, Novartis' postdoctoral programs around the world consistently rank among the Best Places to Work. http://nibr.com/newsroom/stories/2011/2011Mar03_BillSellers.shtml Mar-03-2011 Bill Sellers, Global Head of Oncology since 2005, has been named to the National Cancer Advisory Board (NCAB). Previously with Harvard Medical School and the Dana Farber Cancer Institute, Bill was named, February 24th by the White House. http://nibr.com/newsroom/stories/2011/2011Feb07_GenomicsInstitute.shtml Feb-07-2011 GNF in La Jolla, California, USA was founded in 1999 on the back of the genomics revolution. At that time, sequencing the human genome was a hot scientific goal, and GNF was created to develop genomics-based technology and associated basic research. In 2002, the GNF Board of Directors made the decision to apply the tools and expertise developed there to exploit the human genome effort in the pursuit of drug discovery. The Institute still has a commitment to basic research and technology development, and it is focused on identifying pathways and targets that are relevant to human disease. All technologies that are developed are done with an eye toward enabling biological discovery or accelerating the drug discovery process. http://nibr.com/newsroom/stories/2011/2011Jan14_EpigeneticsPostDoc.shtml Jan-14-2011 The Novartis Institutes for BioMedical Research (NIBR) in collaboration with the Friedrich Miescher Institute (FMI - a research institute of NIBR) in Basel, Switzerland has a variety of postdoctoral positions in the area of epigenetics, focusing on the interface with regenerative medicine, neuroscience, etiology of cancer and immune disorders, and structural biology. http://nibr.com/newsroom/stories/2011/2011Jan05_AFQ056.shtml Jan-05-2011 The Novartis Institutes for BioMedical Research (NIBR) in collaboration with the Friedrich Miescher Institute (FMI - a research institute of NIBR) in Basel, Switzerland has a variety of postdoctoral positions in the area of epigenetics, focusing on the interface with regenerative medicine, neuroscience, etiology of cancer and immune disorders, and structural biology.